4//SEC Filing
Leuthner Brian A 4
Accession 0001127602-18-009804
CIK 0001472091other
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 8:19 AM ET
Size
11.5 KB
Accession
0001127602-18-009804
Insider Transaction Report
Form 4
Leuthner Brian A
Chief Executive Officer
Transactions
- Sale
Common Stock
2018-03-01$14.81/sh−2,500$37,025→ 72,736 total - Sale
Common Stock
2018-03-02$15.08/sh−2,500$37,700→ 70,236 total - Award
Stock Option (Right To Purchase)
2018-03-01+280,000→ 280,000 totalExercise: $14.98Exp: 2028-03-01→ Common Stock (280,000 underlying)
Holdings
- 162,000(indirect: By Spouse)
Common Stock
- 223,622(indirect: By Trust)
Common Stock
Footnotes (6)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F2]The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $14.44 to $15.29 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $14.79 to $15.31 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed as an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- [F5]The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed as an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- [F6]This option, representing a right to purchase a total of 280,000 shares of Common Stock, will become exercisable on March 1, 2019, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.
Documents
Issuer
Edge Therapeutics, Inc.
CIK 0001472091
Entity typeother
Related Parties
1- filerCIK 0001652973
Filing Metadata
- Form type
- 4
- Filed
- Mar 4, 7:00 PM ET
- Accepted
- Mar 5, 8:19 AM ET
- Size
- 11.5 KB